Vivos therapeutics schedules release of full year 2024 financial results and conference call

Littleton, colo., march 28, 2025 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company”) (nasdaq: vvos), a leading medical device and technology company specializing in the development and commercialization of highly effective proprietary treatments for sleep related breathing disorders (including all severities of obstructive sleep apnea (osa) and snoring in adults and moderate to severe osa in children ages 6 – 17), today announced it plans to release its full year 2024 financial results after market close on monday, march 31, 2025.
VVOS Ratings Summary
VVOS Quant Ranking